Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | CCR8 | P51685 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22306200 | 0.74 | F2RL3 (0.39) | CCR1CCR5CCR8PARP1 | |
| SCHEMBL13041957 | 0.72 | DYRK1A (0.36) | CYP1A2 | |
| SCHEMBL10976101 | 0.69 | LMNA (0.38) | KDM4ESMN1; SMN2PARP1 | |
| SCHEMBL20117306 | 0.69 | ADORA2A (0.47) | CCR1CCR5CCR8PDE10ANOS3 | |
| SCHEMBL2053076 | 0.69 | CCR1 (0.36) | CCR1CCR5CCR8PDE10AKDM4E | |
| SCHEMBL19264866 | 0.69 | HSP90AA1 (0.37) | CCR1CCR5CCR8GRIN2B | |
| SCHEMBL12180280 | 0.68 | PDE10A (0.44) | CCR1CCR5CCR8PDE10ANOS3 | |
| SCHEMBL4403649 | 0.68 | NOS3 (0.38) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL24756693 | 0.65 | MAPKAPK2 (0.47) | — | |
| SCHEMBL30968108 | 0.65 | CCR1 (0.39) | CCR1CCR5CCR8NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-8906954-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8466193-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | HDAC8, HDAC1, HDAC5 | CCR1 4541/4885CCR5 4802/4885CCR8 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.